Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：144

作者：

Soverini, Simona ^{[1
]}

Branford, Susan ^{[2
,3
,4
]}

Nicolini, Franck E. ^{[1
,5
]}

Talpaz, Moshe

Deininger, Michael W. N. ^{[6
]}

Martinelli, Giovanni ^{[1
]}

Mueller, Martin C. ^{[7
]}

Radich, Jerald P. ^{[8
]}

Shah, Neil P. ^{[9
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia

[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia

[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia

[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France

[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany

[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA

来源：

LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期

关键词：

BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;

D O I：

10.1016/j.leukres.2013.09.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

引用

页码：10 / 20

页数：11

共 75 条

[21] A CELLULAR ONCOGENE IS TRANSLOCATED TO THE PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA [J].

DEKLEIN, A ;

VANKESSEL, AG ;

GROSVELD, G ;

BARTRAM, CR ;

HAGEMEIJER, A ;

BOOTSMA, D ;

SPURR, NK ;

HEISTERKAMP, N ;

GROFFEN, J ;

STEPHENSON, JR .

NATURE, 1982, 300 (5894) :765-767

[22] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study [J].

Giles, F. J. ;

le Coutre, P. D. ;

Pinilla-Ibarz, J. ;

Larson, R. A. ;

Gattermann, N. ;

Ottmann, O. G. ;

Hochhaus, A. ;

Radich, J. P. ;

Saglio, G. ;

Hughes, T. P. ;

Martinelli, G. ;

Kim, D-W ;

Novick, S. ;

Gillis, K. ;

Fan, X. ;

Cortes, J. ;

Baccarani, M. ;

Kantarjian, H. M. .

LEUKEMIA, 2013, 27 (01) :107-112

[23] PHILADELPHIA CHROMOSOMAL BREAKPOINTS ARE CLUSTERED WITHIN A LIMITED REGION, BCR, ON CHROMOSOME-22 [J].

GROFFEN, J ;

STEPHENSON, JR ;

HEISTERKAMP, N ;

DEKLEIN, A ;

BARTRAM, CR ;

GROSVELD, G .

CELL, 1984, 36 (01) :93-99

[24] Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party [J].

Gugliotta, Gabriele ;

Castagnetti, Fausto ;

Palandri, Francesca ;

Breccia, Massimo ;

Intermesoli, Tamara ;

Capucci, Adele ;

Martino, Bruno ;

Pregno, Patrizia ;

Rupoli, Serena ;

Ferrero, Dario ;

Gherlinzoni, Filippo ;

Montefusco, Enrico ;

Bocchia, Monica ;

Tiribelli, Mario ;

Pierri, Ivana ;

Grifoni, Federica ;

Marzocchi, Giulia ;

Amabile, Marilina ;

Testoni, Nicoletta ;

Martinelli, Giovanni ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Rosti, Gianantonio .

BLOOD, 2011, 117 (21) :5591-5599

[25] Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia [J].

Hehlmann, Ruediger ;

Lauseker, Michael ;

Jung-Munkwitz, Susanne ;

Leitner, Armin ;

Mueller, Martin C. ;

Pletsch, Nadine ;

Proetel, Ulrike ;

Haferlach, Claudia ;

Schlegelberger, Brigitte ;

Balleisen, Leopold ;

Haenel, Mathias ;

Pfirrmann, Markus ;

Krause, Stefan W. ;

Nerl, Christoph ;

Pralle, Hans ;

Gratwohl, Alois ;

Hossfeld, Dieter K. ;

Hasford, Joerg ;

Hochhaus, Andreas ;

Saussele, Susanne .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1634-1642

[26] Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors [J].

Hochhaus, A. .

ANNALS OF ONCOLOGY, 2006, 17 :X274-X279

[27] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [J].

Hochhaus, A. ;

O'Brien, S. G. ;

Guilhot, F. ;

Druker, B. J. ;

Branford, S. ;

Foroni, L. ;

Goldman, J. M. ;

Mueller, M. C. ;

Radich, J. P. ;

Rudoltz, M. ;

Mone, M. ;

Gathmann, I. ;

Hughes, T. P. ;

Larson, R. A. .

LEUKEMIA, 2009, 23 (06) :1054-1061

[28] Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].

Hochhaus, Andreas ;

Saglio, Giuseppe ;

Larson, Richard A. ;

Kim, Dong-Wook ;

Etienne, Gabriel ;

Rosti, Gianantonio ;

De Souza, Carmino ;

Kurokawa, Mineo ;

Kalaycio, Matt E. ;

Hoenekopp, Albert ;

Fan, Xiaolin ;

Shou, Yaping ;

Kantarjian, Hagop M. ;

Hughes, Timothy P. .

BLOOD, 2013, 121 (18) :3703-3708

[29] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase [J].

Hughes, Timothy ;

Saglio, Giuseppe ;

Branford, Susan ;

Soverini, Simona ;

Kim, Dong-Wook ;

Mueller, Martin C. ;

Martinelli, Giovanni ;

Cortes, Jorge ;

Beppu, Lan ;

Gottardi, Enrico ;

Kim, Dongho ;

Erben, Philipp ;

Shou, Yaping ;

Haque, Ariful ;

Gallagher, Neil ;

Radich, Jerald ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4204-4210

[30] Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy [J].

Hughes, Timothy P. ;

Branford, Susan ;

White, Deborah L. ;

Reynolds, John ;

Koelmeyer, Rachel ;

Seymour, John F. ;

Taylor, Kerry ;

Arthur, Chris ;

Schwarer, Anthony ;

Morton, James ;

Cooney, Julian ;

Leahy, Michael F. ;

Rowlings, Philip ;

Catalano, John ;

Hertzberg, Mark ;

Filshie, Robin ;

Mills, Anthony K. ;

Fay, Keith ;

Durrant, Simon ;

Januszewicz, Henry ;

Joske, David ;

Underhill, Craig ;

Dunkley, Scott ;

Lynch, Kevin ;

Grigg, Andrew .

BLOOD, 2008, 112 (10) :3965-3973

← 1 2 3 4 5 6 7 8 →